Expression of VEGF-A/C, VEGF-R2, PDGF-α/β, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma

Modern Pathology

Volumn 21, Issue 7, 2008, Pages 876-884

  Brunner, Markus ^a   Thurnher, Dietmar ^a   Pammer, Johannes ^a   Geleff, Silvana ^a   Heiduschka, Gregor ^a   Reinisch, Christina M ^b   Petzelbauer, Peter ^b   Erovic, Boban M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Bmi 1; C kit; Mcl 1; Merkel cell carcinoma; Receptor tyrosine kinase; Targeted therapies

Indexed keywords

ANTIBODY; BMI1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA; PLATELET DERIVED GROWTH FACTOR BETA; PROTEIN MCL 1; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MERKEL CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; AUSTRIA; CARCINOMA, MERKEL CELL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REPRESSOR PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46049097564     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.63     Document Type: Article

References (71)

1. Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 1999;8:153-158.
2. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003;49:832-841.
3. Veness MJ. Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma): an overview on management. Australas J Dermatol 2006;47:160-165.
4. Poulsen M, Rischin D, Walpole E, et al. High risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study - TROG 96:07. J Clin Oncol 2003;21:4371-4376.
5. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 2006;64:114-119.
6. Suarez C, Rodrigo JP, Ferlito A, et al. Merkel cell carcinoma of the head and neck. Oral Oncol 2004;40:773-779.
7. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;14:1329-1338.
10. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-352.
11. Bobos M, Hytiroglou P, Kostopoulos I, et al. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol 2006;28:99-104.
12. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005;4:315-321.
13. Feinmesser M, Halpern M, Kaganovsky E, et al. C-kit expression in primary and metastatic Merkel cell carcinoma. Am J Dermatopathol 2004;26:458-462.
14. Strong S, Shalders K, Carr R, et al. KIT receptor (CD117) expression in Merkel cell carcinoma. Br J Dermatol 2004;150:384-385.
15. Su LD, Fullen DR, Lowe L, et al. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol 2002;24:289-293.
16. Swick BL, Ravdel L, Fitzpatrick JE, et al. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. J Cutan Pathol 2007;34:324-329.
17. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma. Prognosis and management. Arch Surg 1991;126:1514-1519.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
19. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;15:237-241.
20. Sur M, Alardati H, Ross C, et al. TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol 2007;20:1113-1120.
21. Maubec E, Duvillard P, Velasco V, et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastasizing melanoma, Merkel carcinoma and squamous cell carcinoma of the skin. Ann Dermatol Venereol 2006;133:274-276.
22. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2000;411:355-365.
23. Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000;16:265-271.
24. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
25. Verschuur HP, Rijksen G, Slootweg PJ, et al. Aberrant tyrosine phosphorylation in head and neck tumours and potentially premalignant tissues. Acta Otolaryngol 1995;115:326-327.
26. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17-23.
27. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005;109:227-241.
28. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241-1257.
29. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-6143.
30. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the protooncogene c-kit in acute myeloblastic leukemia cells. Blood 1991;78:2962-2968.
31. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-376.
32. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-1095.
33. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;11:125-134.
34. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
35. Adjei AA, Mandrekar S, Marks RS, et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005;23:3067.
36. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients [abstract]. Proc Am Soc Clin Oncol 2005;23:7508.
37. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63.
38. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573-1581.
39. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006;59:557-563.
40. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003;22:9087-9096.
41. Cho-Vega JH, Rassidakis GZ, Admirand JH, et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004;35:1095-1100.
42. Gleave M, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-479.
43. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-1036.
44. Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995;146:1309-1319.
45. Wacheck V, Cejka D, Sieghart W, et al. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther 2006;5:1348-1354.
46. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995;128:1173-1184.
47. Akgul C, Turner PC, White MR, et al. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 2000;57:684-691.
48. Kozopas KM, Yang T, Buchan HL, et al. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993;90:3516-3520.
49. Backus HH, van Riel JM, van Groeningen CJ, et al. Rb, Mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001;12:779-785.
50. Chung TK, Cheung TH, Lo WK, et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2004;180:63-68.
51. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-199.
52. Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2001;199:90-97.
53. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999;56:73-82.
54. Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006;44:151-157.
55. Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-6140.
56. van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the Bmi-1 proto-oncogene. Genes Dev 1994;8:757-769.
57. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 1998;93:333-336.
58. Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and polycomb-group gene Bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-168.
59. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005;7:86-95.
60. Wang Y, Schulte BA, Zhou D. Hematopoietic stem cell senescence and long-term bone marrow injury. Cell Cycle 2006;5:35-38.
61. Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002;62:4736-4745.
62. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-2412.
63. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521.
64. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B cell non-Hodgkin lymphoma. Blood 2001;97:3896-3901.
65. Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004;203:217-224.
66. Kim JH, Yoon SY, Jeong SH, et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004;13:383-388.
67. Reinisch C, Kandutsch S, Uthman A, et al. BMI-1: a protein expressed in stem cells, specialized cells and tumors of the gastrointestinal tract. Histol Histopathol 2006;21:1143-1149.
68. Song LB, Zeng MS, Liao WT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006;66:6225-6232.
69. Vonlanthen S, Heighway J, Altermatt HJ, et al. The Bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001;84:1372-1376.
70. Meng XX, Liu WH, Liu DD, et al. Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on K562 cells proliferation. Chin Med J 2005;118:1346-1350.
71. Bergsland EK. When does the presence of the target predict response to the targeted agent? J Clin Oncol 2006;24:213-216.